Laurus Labs Limited Cash Flow Conversion Efficiency

Latest as of September 2025: 0.222x

Laurus Labs Limited cash flow conversion efficiency. Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has a cash flow conversion efficiency ratio of 0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs10.93 Billion ≈ $118.22 Million USD) by net assets (Rs49.34 Billion ≈ $533.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Laurus Labs Limited (2013–2026)

Cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2026. This chart illustrates how Laurus Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Laurus Labs Limited share price for real-time trading data and today's change.

Laurus Labs Limited Cash Flow Conversion Ratio Explained

Laurus Labs Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Laurus Labs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Laurus Labs Limited ranked by their cash flow conversion efficiency. Also see market cap of Laurus Labs Limited for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Lamar Advertising Company
NASDAQ:LAMR
0.279x
GD Power Development Co Ltd
SHG:600795
0.121x
iA Financial Corporation Inc
TO:IAG
0.026x
RPM International Inc
NYSE:RPM
0.073x
SOUTH32 Ltd
AU:S32
0.060x
Rede D'Or São Luiz S.A.
SA:RDOR3
-0.078x
SK Telecom Co Ltd ADR
NYSE:SKM
0.086x
Bank of Baroda
NSE:BANKBARODA
-0.146x

Annual Cash Flow Conversion Efficiency for Laurus Labs Limited (2013–2026)

The table below shows the annual cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2026. Review how much free cash does Laurus Labs Limited generate to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-03-31 Rs54.31 Billion
≈ $587.38 Million
Rs14.59 Billion
≈ $157.83 Million
0.269x +105.55%
2025-03-31 Rs46.03 Billion
≈ $497.75 Million
Rs6.02 Billion
≈ $65.07 Million
0.131x -19.18%
2024-03-31 Rs41.16 Billion
≈ $445.08 Million
Rs6.66 Billion
≈ $71.99 Million
0.162x -34.11%
2023-03-31 Rs40.49 Billion
≈ $437.85 Million
Rs9.94 Billion
≈ $107.49 Million
0.245x -9.49%
2022-03-31 Rs33.59 Billion
≈ $363.27 Million
Rs9.11 Billion
≈ $98.53 Million
0.271x -3.76%
2021-03-31 Rs26.01 Billion
≈ $281.26 Million
Rs7.33 Billion
≈ $79.27 Million
0.282x +43.58%
2020-03-31 Rs17.70 Billion
≈ $191.39 Million
Rs3.47 Billion
≈ $37.57 Million
0.196x +2.77%
2019-03-31 Rs15.58 Billion
≈ $168.54 Million
Rs2.98 Billion
≈ $32.19 Million
0.191x -17.32%
2018-03-31 Rs14.83 Billion
≈ $160.34 Million
Rs3.42 Billion
≈ $37.04 Million
0.231x -7.42%
2017-03-31 Rs13.30 Billion
≈ $143.88 Million
Rs3.32 Billion
≈ $35.90 Million
0.250x +9.96%
2016-03-31 Rs8.52 Billion
≈ $92.12 Million
Rs1.93 Billion
≈ $20.90 Million
0.227x +352.81%
2015-03-31 Rs7.21 Billion
≈ $77.96 Million
Rs-647.06 Million
≈ $-7.00 Million
-0.090x -126.54%
2014-03-31 Rs3.58 Billion
≈ $38.76 Million
Rs1.21 Billion
≈ $13.11 Million
0.338x -0.57%
2013-03-31 Rs2.59 Billion
≈ $28.04 Million
Rs882.08 Million
≈ $9.54 Million
0.340x --

About Laurus Labs Limited

NSE:LAURUSLABS India Drug Manufacturers - Specialty & Generic
Market Cap
$13.72 Billion
Rs1.27 Trillion INR
Market Cap Rank
#1706 Global
#56 in India
Share Price
Rs2348.00
Change (1 day)
-2.39%
52-Week Range
Rs944.90 - Rs2405.50
All Time High
Rs2405.50
About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal… Read more